{"id":"NCT05047770","sponsor":"GlaxoSmithKline","briefTitle":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","officialTitle":"A Phase III, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Immune Response and Safety of Both Herpes Zoster Subunit Vaccine in Healthy Adults Aged 50 Years and Older AND the Influenza Virus Vaccine in Healthy Adults Aged 18 Years and Older When Administered Sequentially or Coadministered With mRNA-1273 Booster Vaccination","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-07","primaryCompletion":"2022-08-29","completion":"2022-08-31","firstPosted":"2021-09-17","resultsPosted":"2023-11-13","lastUpdate":"2023-11-13"},"enrollment":2013,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"HZ/su","otherNames":[]},{"type":"COMBINATION_PRODUCT","name":"Flu D-QIV","otherNames":["Flu Quadrivalent Influenza Vaccine"]},{"type":"BIOLOGICAL","name":"mRNA-1273","otherNames":[]}],"arms":[{"label":"HZ/suSeq Group","type":"ACTIVE_COMPARATOR"},{"label":"HZ/suCoAd Group","type":"EXPERIMENTAL"},{"label":"FluD-QIVSeq Group","type":"ACTIVE_COMPARATOR"},{"label":"FluD-QIVCoAd Group","type":"EXPERIMENTAL"}],"summary":"The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, when administered sequentially or co-administered with Moderna's mRNA-1273 booster vaccination against COVID-19.","primaryOutcome":{"measure":"Anti-glycoprotein E (gE) Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) in HZ/suSeq and HZ/suCoAd Groups, and Between-group Ratios","timeFrame":"At 1 month post-dose 2 of HZ/su vaccine administration (Week 14 for HZ/suSeq group and Week 12 for HZ/suCoAd group)","effectByArm":[{"arm":"HZ/suSeq Group","deltaMin":47434.82,"sd":null},{"arm":"HZ/suCoAd Group","deltaMin":47599.82,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":20},"locations":{"siteCount":46,"countries":["United States"]},"refs":{"pmids":["38513689","37781954","37335963"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":272},"commonTop":["Injection site pain","Myalgia","Fatigue","Headache","Chills"]}}